Health experts have been left baffled by a big rise in a common and potentially fatal type of heart attack in the west of Scotland.
During the summer there was a 25 per cent rise in the number of people rushed to the Golden Jubilee National Hospital in Clydebank with partially blocked arteries cutting blood supply to the heart.
According to NIH’s U.S. National Library of Medicine, “A blood clot may block an artery or vein in the heart” which could affect a number of major organs, including the legs, lungs, kidney or heart.
The paper reports over the summer Golden Jubilee saw a 25 percent rise in NSTEMI, or non-ST segment elevation, myocardial infarctions, or heart attacks.
The number of so-called STEMI attacks, where there is extensive heart damage, recorded at the Golden Jubilee has remained stable for a decade at about 750 a year. Yet N-STEMI attacks, where there is less tissue damage but an equal risk of death, have increased over the summer.
In a quote to the paper, Golden Jubilee lead consultant cardiologist Mitchell Lindsay listed off numerous possible causes, but curiously neglected one – the Covid vaccine.
There is not any evidence that it is as a consequence of any delayed care or missed opportunity. It is likely to be due to a multitude of factors: people being sedentary with lockdown; stress; people ignoring symptoms because they do not want to present at hospital. There are probably five to ten causes, all linked.
According to Google statistics, 70.3 percent of Scots are vaccinated, with 76.8 percent having received at least one dose.
Meanwhile, on Twitter, users didn’t hesitate to make the correlation between the so-called mysterious heart attack increase and Covid vaccination.
In February 2018, the Advisory Committee on Immunizations Practices (ACIP) of the Centers for Disease Control and Prevention (CDC) approved the recommendation for a new hepatitis B vaccine, Heplisav-B (HepB-CpG) targeting for adults over the age of 18.1
Heplisav-B is manufactured by Dynavax Technologies Corp. and the new vaccine is given in a two-dose series versus the three dose recommendation for Merck’s Recombivax hepatitis B vaccine licensed in 1986 and Glaxo Smith Kline’s Engerix-B vaccine licensed in 1989.
The U.S. Food and Drug Administration (FDA) had twice rejected Dynavax’s application for licensure for Heplisav-B in the past four years because of safety signals.2
In Dynavax’s third attempt, the FDA granted the license in November 2017, despite unresolved safety concerns. Below is the sequence of events leading to licensure of Heplisav-B.
In 2013, the FDA rejected Dynavax’s license application for Heplisav-B for the first time due to the regulatory agency’s concern that the experimental vaccine’s new adjuvant, which was designed to boost immunogenicity, could lead to development of autoimmune disorders.3
Heplisav-B differs from other licensed hepatitis B vaccines in that it contains a new synthetic adjuvant known as cytosine phosphoguanine 1018 (CpG 1018) composed of short synthetic DNA molecules.4
Hepatitis B vaccines previously licensed in the U.S contain alum adjuvants (aluminum salts), which stimulate a general inflammatory response.3
CpG 1018 is believed to stimulate a more specific inflammatory response by producing hepatitis B surface antigen-specific antibodies against the hepatitis B virus.3
According to an article published in Medscape, the first application by Dynavax Technologies for licensure of Heplisav-B vaccine was rejected by the FDA for the following reason:
Heart attack Testimonies from Israel
Business of Genocide
The Swedish Public Health Agency revealed on Wednesday that it is recommending use of the Moderna SpikeVax be discontinued in young people born after 1991, citing serious cardiac issues incuding myocarditis and pericarditis. Denmark implemented a ban for people aged 12-17 the same week.
“The Swedish Public Health Agency has decided to suspend the use of Moderna’s vaccine Spikevax, for everyone born in 1991 and later, for precautionary reasons,” the Agency stated on Wednesday. “The cause is signals of an increased risk of side effects such as inflammation of the heart muscle or heart sac. However, the risk of being affected is very small.”
“New preliminary [analysis] from Swedish and Nordic data sources indicate that the connection is especially clear when it comes to Moderna’s vaccine Spikevax, especially after the second dose,” the statement continued. “The increase in risk is seen within four weeks after the vaccination, mainly within the first two weeks.”
The statement concluded, “The Swedish Public Health Agency has decided to recommend a break for all use of Spikevax for people born in 1991 and later. The Comirnaty vaccine from Pfizer / Biontech is recommended for these age groups instead. The decision is valid until 1 December 2021. The Swedish Public Health Agency will return with a notice of recommendation after this date.”
On the same day, the Danish Health Authority noted that “In the preliminary data … there is a suspicion of an increased risk of heart inflammation, when vaccinated with Moderna,” while claiming “heart inflammation is an extremely rare side effect that often has a mild course and goes away on its own.”
Canada’s Public Health Agency stated last Friday that “The risk of cardiac complications, including heart inflammation, has been shown to be substantially increased following COVID-19 infections, with the risks higher after the infection than after vaccination.”